Autologous gene‑modified T cells expressing a CD19‑targeted chimeric antigen receptor recognize CD19 on malignant B cells and, via CD3ζ/co‑stimulatory signaling, activate cytotoxic killing, proliferation, and cytokine release. Metabolic armoring enhances T‑cell metabolic fitness and persistence in the tumor microenvironment. Administered after lymphodepletion to promote CAR‑T expansion and engraftment.